SEARCH

SEARCH BY CITATION

References

  • Galanopoulou AS, Buckmaster PS, Staley KJ, Moshe SL, Perucca E, Engel J Jr, Loscher W, Noebels JL, Pitkanen A, Stables J, White HS, O'Brien TJ, Simonato M. (2012) Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 53:571582.
  • Galanopoulou AS, Kokaia M, Loeb JA, Nehlig A, Pitkanen A, Rogawski MA, Staley KJ, Whittemore V, Dudek FE (2013) Epilepsy therapy development: Technical and methodological issues in studies with animal models. Epilepsia 54(Suppl. 4):1323.
  • Kimmelman J, Anderson JA. (2012) Should preclinical studies be registered? Nat Biotechnol 30:488489.
  • Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD. (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490:187191.
  • Prinz F, Schlange T, Asadullah K. (2011) Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10:712.
  • Sarter M, Tricklebank M. (2012) Revitalizing psychiatric drug discovery. Nat Rev Drug Discov 11:423424.